Target Price | $64.20 |
Price | $54.62 |
Potential |
17.54%
register free of charge
|
Number of Estimates | 22 |
22 Analysts have issued a price target Sanofi Sponsored ADR 2026 .
The average Sanofi Sponsored ADR target price is $64.20.
This is
17.54%
register free of charge
$70.21
28.55%
register free of charge
$54.24
0.70%
register free of charge
|
|
A rating was issued by 26 analysts: 21 Analysts recommend Sanofi Sponsored ADR to buy, 4 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sanofi Sponsored ADR stock has an average upside potential 2026 of
17.54%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 44.44 | 50.44 |
8.69% | 13.52% | |
EBITDA Margin | 31.98% | 30.66% |
1.42% | 4.12% | |
Net Margin | 13.54% | 18.24% |
5.23% | 34.70% |
19 Analysts have issued a sales forecast Sanofi Sponsored ADR 2025 . The average Sanofi Sponsored ADR sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Sanofi Sponsored ADR EBITDA forecast 2025. The average Sanofi Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Sanofi Sponsored ADR Analysts have issued a net profit forecast 2025. The average Sanofi Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.40 | 3.67 |
3.00% | 52.92% | |
P/E | 14.89 | |
EV/Sales | 2.87 |
9 Analysts have issued a Sanofi Sponsored ADR forecast for earnings per share. The average Sanofi Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Sanofi Sponsored ADR...
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
BNP PARIBAS EXANE |
Locked
➜
Locked
|
Locked | Jan 05 2025 |
BANCO SANTANDER |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
ODDO BHF |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
TD COWEN |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
LEERINK PARTNERS |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Nov 25 2024 |
Analyst Rating | Date |
---|---|
Locked
BERENBERG:
Locked
➜
Locked
|
Jan 06 2025 |
Locked
BNP PARIBAS EXANE:
Locked
➜
Locked
|
Jan 05 2025 |
Locked
BANCO SANTANDER:
Locked
➜
Locked
|
Dec 17 2024 |
Locked
ODDO BHF:
Locked
➜
Locked
|
Dec 17 2024 |
Locked
TD COWEN:
Locked
➜
Locked
|
Dec 17 2024 |
Locked
LEERINK PARTNERS:
Locked
➜
Locked
|
Dec 16 2024 |
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Nov 25 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.